Literatura académica sobre el tema "High-grade serous ovarian carcinoma"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "High-grade serous ovarian carcinoma".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "High-grade serous ovarian carcinoma"
Casey, Laura y Naveena Singh. "Ovarian High-Grade Serous Carcinoma". Surgical Pathology Clinics 12, n.º 2 (junio de 2019): 515–28. http://dx.doi.org/10.1016/j.path.2019.01.007.
Texto completoPannu, Harpreet K., Weining Ma, Emily Craig Zabor, Chaya S. Moskowitz, Richard R. Barakat y Hedvig Hricak. "Enhancement of Ovarian Malignancy on Clinical Contrast Enhanced MRI Studies". ISRN Obstetrics and Gynecology 2013 (13 de febrero de 2013): 1–8. http://dx.doi.org/10.1155/2013/979345.
Texto completoKshirsagar, Malti, Wei Jiang y Ie-Ming Shih. "DNA Damage Response is Prominent in Ovarian High-Grade Serous Carcinomas, Especially Those with Rsf-1 (HBXAP) Overexpression". Journal of Oncology 2012 (2012): 1–7. http://dx.doi.org/10.1155/2012/621685.
Texto completoVang, Russell, Ie-Ming Shih y Robert J. Kurman. "Ovarian Low-grade and High-grade Serous Carcinoma". Advances in Anatomic Pathology 16, n.º 5 (septiembre de 2009): 267–82. http://dx.doi.org/10.1097/pap.0b013e3181b4fffa.
Texto completoMoss, Esther Louise, Tim Evans, Philippa Pearmain, Sarah Askew, Kavita Singh, Kiong K. Chan, Raji Ganesan y Lynn Hirschowitz. "Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?" International Journal of Gynecologic Cancer 25, n.º 7 (septiembre de 2015): 1201–7. http://dx.doi.org/10.1097/igc.0000000000000477.
Texto completoVoutsadakis, Ioannis A. "Low-grade serous ovarian carcinoma: an evolution toward targeted therapy". International Journal of Gynecologic Cancer 30, n.º 10 (27 de noviembre de 2019): 1619–26. http://dx.doi.org/10.1136/ijgc-2019-000832.
Texto completoKenda Šuster, Nataša, Snježana Frković Grazio, Irma Virant-Klun, Ivan Verdenik y Špela Smrkolj. "Cancer Stem Cell–Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases". International Journal of Gynecologic Cancer 27, n.º 9 (noviembre de 2017): 2006–13. http://dx.doi.org/10.1097/igc.0000000000001105.
Texto completoRicciardi, Enzo, Thaïs Baert, Beyhan Ataseven, Florian Heitz, Sonia Prader, Mareike Bommert, Stephanie Schneider, Andreas du Bois y Philipp Harter. "Low-grade Serous Ovarian Carcinoma". Geburtshilfe und Frauenheilkunde 78, n.º 10 (octubre de 2018): 972–76. http://dx.doi.org/10.1055/a-0717-5411.
Texto completoDe Leo, Antonio, Donatella Santini, Claudio Ceccarelli, Giacomo Santandrea, Andrea Palicelli, Giorgia Acquaviva, Federico Chiarucci et al. "What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors". Diagnostics 11, n.º 4 (14 de abril de 2021): 697. http://dx.doi.org/10.3390/diagnostics11040697.
Texto completoWu, Jingjing y Jian-Jun Wei. "HMGA2 and high-grade serous ovarian carcinoma". Journal of Molecular Medicine 91, n.º 10 (19 de mayo de 2013): 1155–65. http://dx.doi.org/10.1007/s00109-013-1055-8.
Texto completoTesis sobre el tema "High-grade serous ovarian carcinoma"
Everitt, Gemma Louise Ann. "The inflammatory infiltrate of high-grade serous carcinoma omental metastasis". Thesis, Queen Mary, University of London, 2014. http://qmro.qmul.ac.uk/xmlui/handle/123456789/8038.
Texto completoSheets, Jordan N. "Inhibitory Functions of SUSD2 in the Progression of High-Grade Serous Ovarian Carcinoma". Thesis, University of South Dakota, 2017. http://pqdtopen.proquest.com/#viewpdf?dispub=10633628.
Texto completoSushi Domain Containing 2 (SUSD2) encodes a type I transmembrane protein containing several functional domains inherent to adhesion molecules. A clinically annotated HGSOC tissue microarray was stained with an anti-SUSD2 antibody. Patients with tumors that had weak SUSD2 staining had a shorter median survival (31.7 months) compared to patients that had tumors with strong SUSD2 staining (49.1 months; p value = 0.0083).
To investigate the role of SUSD2 in HGSOC, stable OVCAR3, OVSAHO and KURAMOCHI cell lines were established through transfection of shRNA targeted to SUSD2 transcripts (SUSD2 knock-down [KD] cell lines) or non-targeting shRNA (SUSD2 NT) cell lines. Boyden chamber and wound healing assays demonstrated that OVCAR3, OVSAHO and KURAMOCHI SUSD2 KD cells migrated at significantly higher rates than their SUSD2 NT counterpart cell lines. RT-qPCR and western immunoblot analysis indicated an inverse relationship between SUSD2 and well characterized mesenchymal genes, such as TWIST1, ZEB1 and CHD2. In addition, OVCAR3 and KURAMOCHI SUSD2 KD spheroids displayed increased mesothelial clearance ability compared to SUSD2 NT spheroids.
To explore the potential for SUSD2 to inhibit late-stage HGSOC metastasis, female athymic nude mice were injected with either OVCAR3 NT or OVCAR3 KD cells. Fewer nodules were observed in the pancreas and omentum of the OVCAR3 NT mice when compared to the OVCAR3 KD mice. Furthermore, OVCAR3 KD mice had a significantly shorter median survival compared to OVCAR3 NT mice (175 days compared to 185.5 days, respectively; p-value = 0.0047).
KURAMOCHI lysate was immunoprecipitated for SUSD2-associated immunocomplexes and subjected to liquid chromatography, tandem mass spectrometry (LC-MS/MS) analysis, yielding a list of candidate SUSD2-interacting proteins associated with RNA processing. Immunofluorescence analysis of OVCAR3, KURAMOCHI and SKBR3 cells and western immunoblot analysis of their subcellular extracts revealed SUSD2 to be present in cell nuclei, mitochondria and cytoplasm; however, SUSD2 was relatively less abundant in SKBR3 nuclei.
Our findings suggest that increased SUSD2 expression in HGSOC impedes metastasis, consistent with prolonged survival observed in HGSOC patients with high SUSD2-expressing primary tumors. The differences in subcellular distribution between HGSOC cells and breast cancer cells may explain alternate functions of SUSD2 in different cancers.
Cole, Alexander John. "The role of p53 and histone H2B monoubiquitination in high-grade serous ovarian carcinoma". Thesis, The University of Sydney, 2017. http://hdl.handle.net/2123/17639.
Texto completoCheng, Jung-Chien. "Role of E-cadherin in the serous borderline ovarian tumor and low-grade serous ovarian carcinoma cell invasion". Thesis, University of British Columbia, 2012. http://hdl.handle.net/2429/43651.
Texto completoVirtanen, Siru Sirkku Pauliina. "Phenotypic and functional characterisation of cancer stem cells in human high-grade serous ovarian carcinoma". Thesis, University of Cambridge, 2014. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.648879.
Texto completoMurakami, Ryusuke. "Establishment of a novel histopathological classification of high-grade serous ovarian carcinoma correlated with prognostically distinct gene expression subtypes". Kyoto University, 2016. http://hdl.handle.net/2433/215449.
Texto completoDawson, Amy. "Targeted therapy in low-grade serous ovarian carcinoma : characterization of MEK inhibitor response in novel patient-derived cell lines". Thesis, University of British Columbia, 2016. http://hdl.handle.net/2429/59456.
Texto completoMedicine, Faculty of
Graduate
Howe, Eleanor Arden. "MicroRNA expression and activity in high-grade serous ovarian cancer". Thesis, University of Oxford, 2012. http://ora.ox.ac.uk/objects/uuid:9d17590c-550b-4ae9-ac8d-15387cf70e5f.
Texto completoTodeschini, P. "NON-CODING RNAS IN HIGH-GRADE SEROUS EPITHELIAL OVARIAN CANCER". Doctoral thesis, Università degli Studi di Milano, 2016. http://hdl.handle.net/2434/488108.
Texto completoMoore, Elizabeth. "Improving earlier non-invasive diagnosis of high-grade serous ovarian cancer". Thesis, University of Cambridge, 2018. https://www.repository.cam.ac.uk/handle/1810/285405.
Texto completoLibros sobre el tema "High-grade serous ovarian carcinoma"
The Tumor Microenvironment of High Grade Serous Ovarian Cancer. MDPI, 2019. http://dx.doi.org/10.3390/books978-3-03897-555-7.
Texto completoCapítulos de libros sobre el tema "High-grade serous ovarian carcinoma"
Kyo, Satoru. "Investigating the Molecular Carcinogenesis of Ovarian High-Grade Serous Carcinoma". En Current Human Cell Research and Applications, 41–56. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-6013-6_4.
Texto completoGershenson, David M. "The Continuum of Serous Ovarian Tumors of Low Malignant Potential and Low-Grade Serous Carcinoma of the Ovary". En Rare and Uncommon Gynecological Cancers, 105–11. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-642-13492-0_9.
Texto completoShaw, Patricia A., Blaise Clarke y Sophia H. L. George. "Precursors of High-Grade Serous Carcinoma". En Precancerous Lesions of the Gynecologic Tract, 3–22. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-22509-8_1.
Texto completoGershenson, David M. "Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary or Peritoneum". En Ovarian Cancers, 183–200. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-32110-3_13.
Texto completoZeleznik, Oana A., Gerhard G. Thallinger, John Platig y Aedín C. Culhane. "Topological Pathway Enrichment Analysis of Gene Expression in High Grade Serous Ovarian Cancer Reveals Tumor-Stoma Cross-Talk". En Trends in Mathematics, 59–63. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-55639-0_10.
Texto completoPasquini, Luca, Roberta Riccioni y Eleonora Petrucci. "Assessment of Tumor Heterogeneity in High-Grade Serous Ovarian Cancer: Mass Cytometry to Understand the Complex Tumor Biology". En Methods in Molecular Biology, 105–18. New York, NY: Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2513-2_9.
Texto completoKessler, Mirjana. "Role of Infections and Tissue Inflammation in the Pathology of the Fallopian Tube and High-Grade Serous Ovarian Cancer". En Physiology in Health and Disease, 271–312. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-67951-4_9.
Texto completoAsaturova, Aleksandra, Anna Tregubova y Alina Magnaeva. "Molecular Subtypes of High-Grade Serous Ovarian Carcinoma". En Interdisciplinary Cancer Research. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/16833_2022_102.
Texto completoSantin, Alessandro D. "3 Role of Immunohistochemical Expression of HER2/neu in High-Grade Ovarian Serous Papillary Cancer". En Molecular Genetics, Gastrointestinal Carcinoma, and Ovarian Carcinoma, 333–38. Elsevier, 2005. http://dx.doi.org/10.1016/s1874-5784(05)80089-3.
Texto completoIslam, Farhadul. "Enzymes: Tumour Associated Biomarker". En Current Cancer Biomarkers, 180–94. BENTHAM SCIENCE PUBLISHERS, 2023. http://dx.doi.org/10.2174/9789815079364123010012.
Texto completoActas de conferencias sobre el tema "High-grade serous ovarian carcinoma"
Mansouri, H., I. Zemni, O. Jaidane, MA Ayedi, J. Ben Hassouna, M. Hechiche, R. Chargui y K. Ben Rahal. "287 Comparative study of ovarian low-grade and high-grade serous ovarain carcinoma". En IGCS 2020 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2020. http://dx.doi.org/10.1136/ijgc-2020-igcs.247.
Texto completoLiu, Zhaojian y JianJun Wei. "Abstract 133:MiR-182overexpression and ovarian high grade serous carcinoma". En Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-133.
Texto completoChandrasekaran, Akshaya, Mariam Ahmed, Wade Wang, Paula T. Hammond y Kevin M. Elias. "Abstract 6241: PAX8-directed nanotherapeutics for high-grade serous ovarian carcinoma". En Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-6241.
Texto completoVan der Ploeg, P., W. Verhaegh, J. De Hullu, A. Van der Stolpe y J. Piek. "PO-138 Hedgehog signalling pathway activity in high-grade serous ovarian carcinoma". En Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.662.
Texto completoVerhaak, Roel G. W., Kyle Chang, Hoon Kim, Scott L. Carter, Nikolaus Schultz, Fengmei Zhao, Hui Shen et al. "Abstract 4922: Patterns of tumor evolution in high grade serous ovarian carcinoma". En Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-4922.
Texto completoLiu, Jinsong. "Abstract B49: Giant cancer stem cells of high-grade ovarian serous carcinoma ." En Abstracts: AACR Special Conference: Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; October 17-20, 2015; Orlando, FL. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1557-3265.ovca15-b49.
Texto completoKuhn, Elisabetta, Robert J. Kurman, Robert A. Soslow, Guangming Han, Tian-Li Wang y Ie-Ming Shih. "Abstract 221:TP53mutations in serous tubal intraepithelial carcinoma, the putative precursor lesion of ovarian high-grade serous carcinoma". En Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-221.
Texto completoSaglam, O., S. Vyas, B. Reid, J. Permuth y T. Sellers. "326 Clinical outcomes associated with EZH2 expression in high-grade ovarian serous carcinoma". En IGCS Annual 2019 Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-igcs.326.
Texto completoBapat, Sharmila A. y Sagar Varankar. "Abstract 1042: Cellular plasticity and migratory modalities in high-grade serous ovarian carcinoma". En Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-1042.
Texto completoBapat, Sharmila A. y Sagar Varankar. "Abstract 1042: Cellular plasticity and migratory modalities in high-grade serous ovarian carcinoma". En Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-1042.
Texto completoInformes sobre el tema "High-grade serous ovarian carcinoma"
Nolan, Garry P. Organizing the Cellular and Molecular Heterogeneity in High-Grade Serous Ovarian Cancer by Mass Cytometry. Fort Belvoir, VA: Defense Technical Information Center, octubre de 2013. http://dx.doi.org/10.21236/ada599601.
Texto completo